PARMAXPharmaceuticals
Parmax Pharma Ltd — Cash Flow Statement
₹28.44
-9.12%
Parmax Pharma Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | -1.36 Cr | -1.78 Cr | -0.60 Cr | -0.78 Cr | — |
| Capital Expenditure | -0.70 Cr | -1.59 Cr | -0.94 Cr | -1.53 Cr | — |
| End Cash Position | 0.09 Cr | 0.05 Cr | 0.41 Cr | 1.05 Cr | — |
| Beginning Cash Position | 0.05 Cr | 0.41 Cr | 1.05 Cr | 2.75 Cr | — |
| Changes In Cash | 0.04 Cr | -3.21 Cr | -0.65 Cr | -1.69 Cr | — |
| Financing Cash Flow | 1.40 Cr | -1.43 Cr | -0.04 Cr | -0.91 Cr | — |
| Net Other Financing Charges | -0.40 Cr | -2.85 Cr | — | — | — |
| Net Issuance Payments Of Debt | 1.80 Cr | 1.43 Cr | -0.04 Cr | -0.91 Cr | — |
| Net Long Term Debt Issuance | 1.80 Cr | 1.43 Cr | -0.04 Cr | -0.91 Cr | — |
| Investing Cash Flow | -0.70 Cr | -1.59 Cr | -0.94 Cr | -1.53 Cr | — |
| Net PPE Purchase And Sale | -0.70 Cr | -1.59 Cr | -0.94 Cr | -1.53 Cr | — |
| Purchase Of PPE | -0.70 Cr | -1.59 Cr | -0.94 Cr | -1.53 Cr | — |
| Operating Cash Flow | -0.66 Cr | -0.20 Cr | 0.33 Cr | 0.75 Cr | — |
| Change In Working Capital | -0.36 Cr | 3.88 Cr | -1.41 Cr | -1.27 Cr | — |
| Change In Other Current Liabilities | 3.46 Cr | 2.82 Cr | -0.21 Cr | -4.03 Cr | — |
| Change In Other Current Assets | 0.00 | 0.40 Cr | 0.40 Cr | 0.40 Cr | — |
| Change In Inventory | -0.92 Cr | 1.91 Cr | -1.45 Cr | 1.10 Cr | — |
| Change In Receivables | -3.27 Cr | -0.51 Cr | -0.17 Cr | 1.16 Cr | — |
| Other Non Cash Items | 1.07 Cr | — | — | — | — |
| Deferred Tax | -0.30 Cr | 0.09 Cr | -0.19 Cr | -0.22 Cr | — |
| Depreciation And Amortization | 1.03 Cr | 1.71 Cr | 1.88 Cr | 1.93 Cr | — |
| Depreciation | 1.03 Cr | 1.71 Cr | 1.88 Cr | 1.93 Cr | — |
| Net Income From Continuing Operations | -2.09 Cr | -5.66 Cr | 0.05 Cr | 0.30 Cr | — |
| Other Cash Adjustment Outside Changein Cash | — | 2.85 Cr | — | 1.00 | -1.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Parmax Pharma Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.